Literature DB >> 10402636

Contemporary radiotherapy for soft tissue sarcoma.

J P Wylie1, B O'Sullivan, C Catton, E Gutierrez.   

Abstract

This review will detail the role of radiotherapy in the management of soft tissue sarcoma. Particular emphasis will be given to its role as an adjuvant to surgical excision for local curative management. The addition of radiotherapy permits a tissue-conserving operation to be performed, which has functional and cosmetic advantages yet produces local control equivalent to more radical surgery alone. The review will consider the historical evolution of treatment up through recent and contemporary practice. The principles of use will be outlined using available evidence and, where this is lacking, it will be acknowledged with suggestions for improvement. Finally, a brief overview of some technical issues about radiotherapy will be provided.

Entities:  

Mesh:

Year:  1999        PMID: 10402636     DOI: 10.1002/(sici)1098-2388(199907/08)17:1<33::aid-ssu5>3.0.co;2-n

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  4 in total

Review 1.  Adjuvant therapy for extremity sarcomas.

Authors:  Michael Schlieman; Richard Smith; William G Kraybill
Journal:  Curr Treat Options Oncol       Date:  2006-11

2.  Extraskeletal myxoid chondrosarcoma of the vulva: A case report.

Authors:  Alisa Villert; Larisa Kolomiets; Nikolay Vasilyev; Vladimir Perelmuter; Olga Savenkova
Journal:  Oncol Lett       Date:  2015-08-11       Impact factor: 2.967

Review 3.  Reconstruction for lower extremity limb salvage in soft tissue carcinoma.

Authors:  Neal S Topham
Journal:  Curr Treat Options Oncol       Date:  2003-12

4.  Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma.

Authors:  William G Rule; Jacob B Allred; Barbara A Pockaj; Svetomir N Markovic; David J DiCaudo; Lori A Erickson; Richard L Deming; Steven E Schild
Journal:  Cancer Med       Date:  2016-07-01       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.